NCT04559230招募中2 期
A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio3 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2022年1月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 3
- 主要终点
- Overall survival (OS)
研究概览
简要总结
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.
详细描述
Subjects are expected to participate for up to treatment duration with continued follow up for survival until one year after the last dose of study drug. The total duration of the active part of the study for each subject will be approximately 18 weeks, divided as follows:
- Up to 3 weeks predose (screening period)
- 3-week treatment periods of Sacituzumab govitecan
- Study termination visit 3-4 weeks after last dose of study medication
When a subject has completed the study termination or early termination visit, he/she and/or a family member will be contacted for survival information every 3 months until one year from last study dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age.
- •Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee.
- •Histologically confirmed IDH wild type (primary) GBM. Molecular GBM (as per cIMPACT-NOW 3) is allowed as is gliosarcoma and epithelioid glioblastoma. IDH-mutant glioma is not allowed.
- •Progression following standard combined modality treatment with radiation and temozolomide chemotherapy if O6-Methylguanine-DNA Methyltransferase (MGMT) methylated.
- •Prior temozolomide is not required for MGMT unmethylated, but patient must have received standard doses of radiation.
- •Inclusion of additional investigational therapy with standard frontline therapy is not exclusionary. No additional lines of therapy given for recurrent disease.
- •Prior tumor-treating field therapy is not excluded, nor considered and additional line of therapy as this is often given concurrently with other therapy lines.
- •Patients may have had been operated for recurrence, but if operated must have had surgery a minimum of 2 weeks prior to enrollment and have an MRI completed within 48 hours following surgery.
- •No radiotherapy within the 3 months prior to the diagnosis of progression.
- •Willingness to forego tumor-treatment field (Optune) therapy during participation in the study.
- •Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.
- •Recovered from toxicities of prior therapy to grade 0 or 1, except for neuropathy (Grade ≤2) and alopecia.
- •ECOG performance status ≤
- •Life expectancy of at least 6 months.
- •Acceptable liver function:
- •Bilirubin ≤ 1.5 times upper limit of normal
- •AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN)
- •Acceptable renal function:
- •Creatinine clearance ≥30 mL/minute according to the Cockcroft and Gault formula
- •Acceptable hematologic status (without hematologic support):
- •ANC ≥1500 cells/uL
- •Platelet count ≥100,000/uL
- •Hemoglobin ≥9.0 g/dL
- •All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.
- •Availability of biological material for central review and biomarker evaluation.
- •Untreated recurrent or residual disease that is measurable by RANO criteria at time of enrollment. Multifocal and infratentorial disease is allowed.
- •Positive Trop-2 expression (H-Score ≥200), as verified by central review at University of Texas Health Science Center at San Antonio (UTHSA).
排除标准
- •Prior treatment with bevacizumab or other VEGF inhibitors or VEGF-Receptor signaling inhibitors
- •The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug.
- •3 The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible.
- •The subject is unable to undergo MRI scan (eg, has pacemaker).
- •The subject has received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone).
- •The subject is pregnant or breast-feeding.
- •The subject has serious intercurrent illness, such as:
- •hypertension (two or more blood pressure [BP] readings performed at screening of > 150 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment
- •non-healing wound, ulcer, or bone fracture
- •significant cardiac arrhythmias
- •untreated hypothyroidism
- •unhealed rectal or peri-rectal abscess
- •uncontrolled active infection
- •symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug
- •any history of cardiac arrhythmia or heart block
- •stroke or transient ischemic attack within 6 months
- •The subject has received any of the following prior anticancer therapy:
- •Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic radiosurgery (SRS) is allowed
- •Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 7 days or 5 half-lives, whichever is shorter, prior first dose of study drug
- •Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug
- •Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug
- •Prior treatment with carmustine wafers
- •Patients with radiographically or clinically apparent leptomeningeal involvement are excluded.
研究组 & 干预措施
Sacituzumab govitecan
Experimental
Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle
干预措施: Sacituzumab Govitecan (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: 6 months
Overall survival at 6 months including participants whose disease state has progressed
次要结局
- Progression free survival (PFS)(6 months)
- Overall Response Rate (ORR)(6 week intervals for 6 months, then every 3 months until End of Treatment ( defined as evidence of significant treatment related toxicity or progressive disease))
研究者
William Kelly
Clinical Investigator
The University of Texas Health Science Center at San Antonio
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric AdenocarcinomaEsophagogastric AdenocarcinomaNCT06123468Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest58
已完成
2 期
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)Non-Hodgkin's LymphomaNCT00517049Genentech, Inc.49
招募中
2 期
Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic CancerNon-Resectable Pancreas CarcinomaNCT06393166Zhejiang Cancer Hospital37
已完成
2 期
Study of CM310 in Patients With Allergic RhinitisAllergic RhinitisNCT05908721Keymed Biosciences Co.Ltd100
已完成
2 期
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaGenetic DisordersNCT00261053Pharming Technologies B.V.14